Development of Translatable Immunologically Safe PEGylated Lipid Nanoparticles for mRNAVaccine Delivery (2025-2026)
Abstract
The goal of this project is to address emerging concerns regarding the immunosafety of lipid nanoparticles (LNPs) used in delivering mRNA vaccines, particularly focusing on the immunogenicity triggered by poly(ethylene glycol) (PEG), a crucial hydrophilic polymer stabiliser used in LNP formulations. We propose substituting the immunogenic PEG in LNP formulations with a superior class of hydrophilic sulfoxide polymers that demonstrate enhanced stealth performance and lower immunogenic risk. Through this substitution, the project will develop advanced LNPs with improved immunosafety for safer and more effective delivery of mRNA vaccines.